Human IL-27 Alexa Fluor® 350-conjugated Antibody
Human IL-27 Alexa Fluor® 350-conjugated Antibody Summary
Arg21-Lys229 of EBI-3 (Accession #Q14213.2) and Phe29-Pro243 of p28 (Accession #AAM34498)
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
IL-27 is a heterodimeric group 2 receptor ligand molecule that belongs to the IL-6/IL-12 family of long type I cytokines (1). It is composed of EBI3 (EBV-induced gene 3), a 34 kDa glycoprotein that is related to the p40 subunit of IL-12 and IL-23, and p28, the 28 kDa glycoprotein that is related to the p35 chain of IL-12 (2-4). The human EBI3 gene encodes a 229 amino acid (aa) precursor that contains a 20 aa signal peptide and 209 aa mature protein (5). The mature region contains two potential N-linked glycosylation sites, two fibronectin type III domains, and two pairs of conserved cysteine residues with a WSXWS-like motif that places the molecule in the hematopoietin receptor family (5). Although p40, the EBI3 counterpart in IL-12, is known to form homodimers, there is no evidence to date that EBI3 also homodimerizes. Human EBI3 is 61% aa identical to mouse EBI3. The human p28 gene encodes a 243 aa precursor that contains a 28 aa signal sequence and 215 aa mature region (6). The mature region is characterized by the presence of four alpha -helices, placing it in the IL-6 family of helical cytokines. Human p28 is 74% aa identical to mouse p28. IL-27 is expressed by monocytes, endothelial cells and dendritic cells (7). IL-27 binds to and signals through a heterodimeric receptor complex composed of WSX-1 (TCCR) and gp130. Evidence suggests IL-27 interacts only with WSX-1 (6, 8, 9). IL-27 has both anti- and proinflammatory properties. As an anti‑inflammatory, IL-27 seems to induce a general negative feedback program that limits T and NK-T cell activity (3, 7). At the onset of infection, IL-27 induces an IL‑12 receptor on naïve CD4+ T cells, making them susceptible to subsequent IL-12 activity (and possible Th1 development) (10).
- Boulay, J-L. et al. (2003) Immunity 19:159.
- Trinchieri, G. et al. (2003) Immunity 19:641.
- Murakami, M. et al. (2004) Growth Factors 22:75.
- Cordoba-Rodriguez, R. and D.M. Frucht (2003) Exp. Opin. Biol. Ther. 3:715.
- Devergne, O. et al. (1996) J. Virology 70:1143.
- Pflanz, S. et al. (2002) Immunity 16:779.
- Villarino, A.V. et al. (2004) J. Immunol. 173:715.
- Pflanz, S. et al. (2004) J Immunol 172:2225.
- Scheller, J. et al. (2005) Biochem. Biophys. Res. Commun. 326:724.
- Holscher, C. (2004) Med. Microbiol. Immunol. (Berl).193:1.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human IL-27 Alexa Fluor® 350-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human IL-27 Alexa Fluor® 350-conjugated Antibody and earn rewards!
Have you used Human IL-27 Alexa Fluor® 350-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image